Rain Oncology Inc. Common Stock
RAIN
RAIN was delisted on the 25th of January, 2024.
46 hedge funds and large institutions have $172M invested in Rain Oncology Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 3 closing their positions.
1,000% more call options, than puts
Call options by funds: $11K | Put options by funds: $1K
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
145% more capital invested
Capital invested by funds: $70M → $172M (+$102M)
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
21% more funds holding
Funds holding: 38 → 46 (+8)
10.26% more ownership
Funds ownership: 76.23% → 86.49% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$17.6M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$6.1M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.4M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.09M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.07M |
| 2 |
BlackRock
New York
|
-$556K |
| 3 |
E
Ergoteles
New York
|
-$318K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$221K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$160K |
RAIN Hedge Fund Activity: Q4 2022 in Review
46 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q4 2022, worth a combined $172M — up 145% from $70M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RAIN positions and 3 closed out — a net gain of 8 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $17.6M. The largest seller was Fidelity Investments, cutting an estimated $1.07M.
- 46 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q4 2022, up from 38 in Q3 2022.
- Funds reported $172M of Rain Oncology Inc. Common Stock stock for Q4 2022, up 145% quarter-over-quarter.
- 11 funds opened new Rain Oncology Inc. Common Stock positions in Q4 2022 and 3 closed out, a net change of +8 holders.
- The largest Rain Oncology Inc. Common Stock buyer in Q4 2022 was Deerfield Management, an estimated $17.6M added.
- The largest Rain Oncology Inc. Common Stock seller in Q4 2022 was Fidelity Investments, an estimated $1.07M sold.
Based on aggregated 13F filings for Q4 2022.